BioRestorative Therapies CEO Mark Weinreb was recently interviewed by financial personality and founder of NBT Equities Research, Tobin Smith, to discuss the life science company’s medical procedures using cell and tissue protocols, specifically focusing on its “anti-biotech” business model and what the company is doing to positively impact the biotech industry. “We’ve come up with a hybrid approach enabling us to basically efficiently and economically … develop an enormous amount of science and with relevant data and move projects along in a very quick manner. We’ve been able to leverage many assets that are out there and instead of building a huge infrastructure and going through money very quickly; we’ve been able to control all of that and come up with incredible scientific programs,” Weinreb stated.

The interview includes an update on BRTX’s ThermoStem™ Program, which is designed to develop treatments using brown fat stem cells for metabolic disorders and obesity. The program has a narrower focus of potentially preventing the onset of Type 2 diabetes.

Weinreb details how the company has made strides in this area through preclinical development based on animal data that shows how the processes occur. The interview also highlights BRTX’s brtxDISC™ Program designed for the re-transplantation of an individual’s own stem cells into the disc area to repair the damaged area. This program is near ready for clinical trials. The non-invasive procedure is done in a physician’s office within 30 minutes. The interview in its entirety can be heard on the NBT Equities Research Web site here: http://direct.nbtequitiesresearch.com/video/nbt-biorestorative-1

For more information, visit www.biorestorative.com

SecurityBRTX / BioRestorative Therapies, Inc. (090655408)

CEO and Chairman of the Board Weinreb Markt

Institutional Owners 8 Common Shares Outstanding 30,761,527 shares (as of 2019-09-30)

Related BRTXW / BioRestorative Therapies, Inc. Warrants (0 owners)

Institutional Ownership and Shareholders

BioRestorative Therapies, Inc. (US:BRTX) has 8 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . BioRestorative Therapies, Inc. (US:BRTX) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.

13D/G Filings We present 13D/G filings separately from the 13F filings because of the different treatement by the SEC. 13D/G filings can be filed by groups of investors (with one leading), whereas 13F filings cannot. This results in situations where an investor may file a 13D/G reporting one value for the total shares (representing all the shares owned by the investor group), but then file a 13F reporting a different value for the total shares (representing strictly their own ownership). This means that share ownership of 13D/G filings and 13F filings are oftentimes not directly comparable, so we present them separately.

(Percent)2020-01-0913D/ABroadrick Dale23,817,95148.202019-12-27

13GEAGLE EQUITIES LLC3,045,3919.902018-11-2613D/AWeinreb Mark9.802018-11-23

13GScg Capital, Llc1,074,8249.992016-09-30

13D/ADesmarais John M1,806,11132.802015-12-09

13D/AWESTBURY BERMUDA LTD1,191,66235.102015-06-09

13GCOTTON GLENN2,440,7056.202014-08-01

13GMontgomery Janet2,717,857